NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-173-2020-0-CA-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 CA National Stage 3191186 Pending
NCI E-167-2019-0-CA-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY CA National Stage 3191211 Pending
NCI E-173-2018-2-AU-01 Viral Methods Of T Cell Therapy AU DIV 2023201224 Pending
NIAID E-189-2023-0-KR-01 COMPOSITION FOR PREVENTING OR TREATING SYSTEMIC CAPILLARY LEAK SYNDROME KR ORD 10-2023-0027030 Pending
NCATS E-014-2022-0-US-02 HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF US National Stage 18/043,163 Pending
NCI E-149-2015-0-US-02 METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD US CON 18/174,928 Pending
NCI E-050-2014-0-US-02 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS USING A VLP-REPLICON US DIV 18/174,013 Pending
NHLBI E-126-2020-0-US-02 Methods To Produce Very Long Chain Fatty Acids (VLCFA) US National Stage 18/042,743 Pending
NIAID E-288-2016-0-US-02 Biomarkers And Vaccine Candidates For Filarial Parasites US DIV 18/173,288 Pending
NCI E-173-2020-0-SG-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATIONS IN P53 SG National Stage 11202301360P Pending
NCI E-087-2015-1-US-04 METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE USING
CONSERVED ELEMENT CONSTRUCTS 		US CON 18/171,804 Pending
NIAID E-052-2017-4-CN-03 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection CN DIV 202310147287.X Pending
NCI E-167-2019-0-AU-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY AU National Stage 2021341969 Pending
NCI E-109-2020-0-JP-01 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES JP National Stage 2023-512482 Pending
NHLBI E-126-2020-0-IL-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) IL National Stage 2068-07-30 Pending
NINDS E-146-2016-1-US-02 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE US CON 18/111,241 Pending
NCI E-172-2020-0-CN-01 HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION CN National Stage 202180050745.7 Pending
NICHD E-018-2022-0-PC-01 METHODS OF TREATING NEONATAL LIVER DISEASE PCT PCT PCT/US2023/062843 Pending
NCATS E-116-2016-0-US-12 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6,)-HYDROXYNORKETAMINE US CON 18/170,048 Pending
NCI E-163-2020-0-AU-01 LZK-TARGETING DEGRADERS AND METHODS OF USE AU National Stage 2021336300 Pending
NCI E-025-2022-0-PC-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF PCT PCT PCT/US2023/062525 Pending
NCI E-172-2020-0-KR-01 HLA Class-II Restricted DRB1*01:01 T-cell Receptors Against The RASG12V Mutation KR National Stage 20237005176 Pending
NCI E-183-2017-0-JP-01 ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS JP DIV 2023-020373 Pending
NIAAA E-282-2012-0-US-02 CANNABINOID RECEPTOR MEDIATING COMPOUNDS US CON 18/108,264 11939297 Issued PDF
NCI E-172-2020-0-EP-01 HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION EP National Stage 21752355.4 Pending
NCI E-165-2020-0-EP-01 HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation EP National Stage 21751702.8 Pending
NCATS E-200-2020-0-US-04 Realtime Cellular Thermal Shift Assay (RT-CETSA) For Research And Drug Discovery US National Stage 18/020,843 Pending
NCI E-109-2020-0-US-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES US National Stage 18/020,823 Pending
NEI E-195-2020-0-US-03 SAMPLE PREPARATION AND VIRAL DETECTION METHODS US National Stage 18/041,295 Pending
NIAID E-047-2022-0-PC-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses PCT PCT PCT/US2023/062324 Pending
NCI E-181-2021-0-PC-01 COMBINATION IMMUNOTHERAPY FOR TREATING CANCER PCT PCT PCT/US2023/062288 Pending
NCI E-107-2020-0-EP-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS EP National Stage 21762956.7 Pending
NCI E-165-2020-0-KR-01 HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation KR National Stage 2023-7004523 Pending
NCI E-107-2020-0-US-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS US National Stage 18/020,191 Pending
NCI E-028-2015-1-AU-01 Anti-Mutated Kras T Cell Receptors AU DIV 2023200614 Pending
NIAID E-279-2016-1-US-11 HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE US CON 18/164,988 Pending
NIA E-249-2016-0-JP-01 METHODS OF DELIVERING A NEUROPROTECTIVE POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM JP DIV 2023-16292 Pending
NCI E-176-2014-0-AU-01 Anti-Human Papillomavirus 16 E7 T Cell Receptors AU DIV 2023200608 Pending
NEI E-004-2017-0-JP-01 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY JP DIV 2023-015034 Pending
NICHD E-185-2020-0-US-03 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo US National Stage 18/019,725 Pending
NCI E-165-2020-0-AU-01 HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation AU National Stage 2021310213 Pending
NIAID E-241-2014-0-US-02 RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 1 (HPIV1) EXPRESSING A CHIMERIC RSV/HPIV1 F PROTEIN AND USES THEREOF US CON 18/162,530 Pending
NCATS E-218-2021-0-PC-01 SMALL MOLECULE AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF PCT PCT PCT/US2023/012013 Pending
NINDS E-120-2020-2-EP-03 ADAPTABLE DUAL-TUNED OPTICALLY CONTROLLED ON-COIL AMPLIFIER FOR HIGH-FIELD MAGNETIC RESONANCE IMAGING SYSTEMS EP National Stage 21746288.6 Pending
NCI E-196-2018-0-US-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS US National Stage 18/018,762 Pending
NHLBI E-191-2020-0-CN-03 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT CN National Stage 202180059611.1 Pending
NHLBI E-035-2022-0-PCT-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) PCT PCT PCT/US2023/011640 Pending
NHLBI E-191-2020-0-US-06 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT US National Stage 18/006,331 Pending
NICHD E-170-2020-0-US-03 TIME EFFICIENT MULTI-PULSED FIELD GRADIENT (MPFG) MRI WITHOUT CONCOMITANT GRADIENT FIELD ARTIFACTS US National Stage 18/017,150 Pending
NIA E-024-2022-0-PC-01 GINGERENONE A PRODRUGS AS SENOTHERAPEUTICS AND METHODS OF USE PCT PCT PCT/US2023/010962 Pending